For patients with systemic hypoxia and patent foramen ovale (PFO), transcatheter closure of the defect reduces oxygen requirements while improving symptoms and evidence of right-to-left shunt. The ...

WASHINGTON — Final results of the RESPECT trial showed that percutaneous patent foramen ovale closure reduced the risk for recurrent stroke compared with guideline-directed medical therapy alone over ...

Percutaneously closing a patent foramen ovale (PFO) using the Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent ischemic stroke in patients who previously had a ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

MIAMI BEACH, FLA.—Results from two randomized trials presented at TCT 2012—RESPECT and PC—address patent foramen ovale (PFO) closure for secondary stroke prevention in patients with cryptogenic ...

WASHINGTON, Oct. 31 (UPI) --The U.S. Food and Drug Administration has approved the Amplatzer PFO Occluder device for select patients to reduce their risk of recurrent strokes. The PFO Occluder is a ...

ST. PAUL, Minn. & WASHINGTON--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the long-term data from RESPECT, a landmark trial, during a First ...

Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

A practice advisory update from the American Academy of Neurology (AAN) warns against routinely offering percutaneous closure of patent foramen ovale (PFO) in patients with cryptogenic ischemic stroke ...

Abbott Laboratories ABT recently received FDA approval for its Amplatzer Talisman PFO Occlusion System to treat patent foramen ovale (PFO) patients at risk of recurrent ischemic stroke. The ...

A group of doctors convened by the Food and Drug Administration decided Tuesday that a new St. Jude Medical heart device to prevent strokes appears safe and effective, after more than 13 years of U.S.

- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible ...